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nemia in Heart Failure
arker or Mediator
f Adverse Prognosis?*
ayne C. Levy, MD, FACC
eattle, Washington
A dropsy first shows itself, by the swelling of the legs about the
ankles, in such a manner as to retain the impression of your
finger. The swelling appear most at night, and is usually
attended with a shortness and difficulty of breath, ever most
troublesome when the patient lies down.
He must therefore resolve upon proper remedies, before the
waters rise high enough to drown; and, if he have but the gift
of self denial, he may, by God’s Help, get the better of this mortal
enemy; provided there be no universal decay, no depravation
of the liver, or other organs, necessary for blood-making.
John Tennent, The Poor Planter’s Physician, 1736 (1)
t has long been known that anemia portends a poor
rognosis in the general population (2) and in patients with
ypertension (3), chronic kidney disease (4), cancer, acute
yocardial infarction (5), coronary artery bypass grafting
6), percutaneous coronary intervention (7), and heart fail-
re (HF) (8,9), as described by John Tennent almost 3
enturies ago. What is uncertain is whether anemia is
nother marker of inflammation, and thus a risk marker like
-reactive protein, phospholipase A2, and high white blood
ell count, or whether anemia is a mediator of the adverse
rognosis in these diverse settings. If anemia is a marker,
reatment may not obviate the increased risk associated with
nemia. If it is a mediator, treatment may be a novel tool to
educe morbidity and mortality in HF.
See page 569
In HF patients, the prevalence of anemia is higher with
dvanced New York Heart Association functional class,
lder age, worse renal function, and more comorbidities. In
he paper by Tang et al. (10) in this issue of the Journal,
nemia was associated with older age; diabetes mellitus;
ale gender; lower glomerular filtration rate; higher ejection
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the University of Washington, Seattle, Washington. Dr. Levy is an Editorial
oard member of the nonprofit National Anemia Action Council and Steerings
ommittee member of RED-HF, a trial of darbepoetin in anemic heart failure
atients.raction; diuretic use; and neurohormonal activation, exem-
lified by low serum sodium, low total cholesterol, and high
-type natriuretic peptide (10). Although angiotensin-
onverting enzyme inhibitors and angiotensin receptor
lockers may lower hemoglobin levels by 0.3 g/dl (3), the
se of angiotensin-converting enzyme inhibitors and beta-
lockers was less common in the anemic patients.
The paper by Tang et al. (10) demonstrates that persis-
ent or new-onset anemia confers a marked increase in risk
or HF patients, whereas anemia that resolved, which
ccurred in 43% of anemic patients, did not confer increased
isk. For each 1 g/dl decrease in hemoglobin, there was a
0% increase in the multivariate adjusted risk of death. This
s similar to or higher than previous analyses of the risk
ssociated with anemia. We do not know whether specific
reatment for the anemia, such as intravenous iron or
rythropoiesis-stimulating proteins (ESP), would also
bviate the risk associated with anemia.
Cardiologists have only lately started to recognize, eval-
ate, and treat anemia. The 2001 American College of
ardiology/American Heart Association HF guidelines
ake no mention of anemia as a risk factor or target for
reatment (11). Tang et al. (10) found that 20% of all
nemic HF patients had a laboratory evaluation for the
nemia, and only 30% had a repeat hemoglobin within 6
onths. Tang et al. (10) state that “hemoglobin levels have
ot been commonly recognized as relevant measurement in
he management of heart failure until recently.”
Anemia should be evaluated with standard laboratory
ests, including iron saturation, ferritin, folate, vitamin B12,
eticulocyte count, stool guaiac, and possibly erythropoietin
evels and soluble transferrin receptors. In diseases where
nflammation is present, such as HF, ferritin may be falsely
levated like other acute-phase response proteins. A very
imple method to determine whether a low iron saturation
s due to anemia of chronic disease or iron deficiency is to
erform an oral iron absorption test (12,13). This test can be
erformed in the outpatient or inpatient setting by admin-
stering 10 ml of ferrous sulfate solution (650 mg) orally and
easuring the serum iron level at baseline and 2 h later. A
ormal response, suggesting that the oral iron is being
bsorbed and transported to the bone marrow, is an increase
f 150 g/dl in the iron level (i.e., 25 to 175 g/dl). This
uggests that the low iron level can be treated with oral iron.
n increase of 50 g/dl suggests that there is a failure of
he oral iron to reach the systemic circulation. I suspect that
his may be due to interruption of the intestinal mucosa by
ut edema in HF patients and to elevated levels of hepcidin.
f patients have a low iron saturation and absorb oral iron
ppropriately, then they likely have iron-deficiency anemia,
nd the hemoglobin will respond to iron repletion (13). If
atients do not absorb oral iron, they may have anemia of
hronic disease and will likely require intravenous iron
herapy. Newer intravenous iron preparations such as iron
ucrose and ferric gluconate have a much lower incidence of
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Editorial Comment February 5, 2008:577–8dverse side effects than older agents such as iron dextran
nd can be used in patients who do not adequately absorb
ral iron. Intravenous iron therapy alone may improve
nemia in many HF patients (14) and is being studied in a
arge randomized trial, IRON-HF (15).
What is unknown is whether treatment of anemia with
SPs is beneficial in cardiac patients. Erythropoietin receptors
re present in the myocardium (16) and throughout many
rgans. In the normal subject, as the hemoglobin decreases, the
rythropoietin levels increase, with a level of 25 mU/ml at a
emoglobin of 12 g/dl and 100 mU/ml at a hemoglobin of
0 g/dl (17). Erythropoietin levels below these values suggest
elative levels of deficiency. The ESPs work by inhibiting
poptosis of the erythroblasts in the bone marrow (18). This
nti-apoptotic effect may be detrimental in cancer patients
19), but it might be beneficial in cardiac patients. In animal
odels, treatment with ESPs prevented cardiomyocyte apop-
otis induced by ischemia (20) and norepinephrine (21).
Phase 2 clinical trials of ESPs in HF patients (n  475
atients) have shown that ESPs can increase hemoglobin,
mproveHF symptoms, and improve exercise capacity andmay
educe morbidity/mortality (hazard ratio 0.67, 95% confidence
nterval 0.44 to 1.03, p  0.07) (22). This hypothesis is being
ested in an ongoing trial, the RED-HF (Reduction in Events
ith darbepoetin alfa in Heart Failure) trial, a double-blind
andomized trial in 3,400 anemic New YorkHeart Association
unctional class II to IV systolic HF patients.
Recent trials in chronic kidney disease patients (23) found
hat attempting to normalize the hemoglobin with higher
oses of ESPs (rather than using ESPs to keep the hemo-
lobin in the 11 to 12 g/dl range) was associated with harm.
e do not know why this harm might have occurred, but it
as led to labeling changes for ESP agents to target the
emoglobin to the 11 to 12 g/dl range.
In conclusion, anemia is prevalent in medical practice and
onfers an adverse risk in most diseases. Anemia may be
ransient and resolve without specific intervention, for
xample, in gastrointestinal blood loss, recent hospitaliza-
ion, acute myocardial infarction, or surgery. If anemia
ersists, evaluation and treatment of the underlying cause is
ppropriate. We do not know whether resolution of the
nemia with treatment will obviate the risk, as was observed
ith spontaneous resolution of anemia by Tang et al. (10).
andomized trials of intravenous iron or ESPs to treat
nemia in HF are ongoing. Only then will we know whether
nemia is a marker or a mediator of the adverse risk in HF.
eprint requests and correspondence: Dr. Wayne C. Levy,
niversity of Washington, Box 356422, 1959 NE Pacific Street,
eattle, Washington 98177. E-mail: levywc@u.washington.edu.
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